Company news

Nippon Shinyaku Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nippon Shinyaku Enters into Exclusive Sublicense Agreement with Tanabe Pharma to Commercialize loncastuximab tesirine-lpyl (MT-2111) for Relapsed or Refractory Diffuse Large B-cell Lymphoma in Japan

October 29, 2026

SAKIGAKE Pharmaceutical Product (Pioneering Drug) Designation Granted to NS-035 for the Treatment of Fukuyama Congenital Muscular Dystrophy

August 26, 2026

Notice Regarding Completion of Disposal of Treasury Stock as Restricted Stock Compensation

August 19, 2026

Regarding the U.S. Litigation Concerning CAP-1002 (deramiocel) – U.S. Court Denies Motion for Preliminary Injunction and Refers Dispute to Arbitration

August 9, 2026

Consolidated Financial Results for the First Quarter of Fiscal Year 2026(IFRS)

August 5, 2026

Exercises Option Rights for Commercialization of AB2 Bio’s Tadekinig alfa in the U.S.

July 30, 2026

Nippon Shinyaku Enters into an Exclusive License Agreement for the Development, Manufacturing, and Commercialization of NS-025 Worldwide

July 22, 2026

Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation

July 21, 2026

Nippon Shinyaku and Elixirgen Enter into an Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy

June 26, 2026

Orphan Drug Designation granted to NS-035 for the Treatment of Fukuyama congenital muscular dystrophy in Japan

June 23, 2026

Nippon Shinyaku Enters into a Sponsored Research Agreement with Boston Children’s Hospital

June 23, 2026

Outline of Consolidated Financial Results for the Year Ended March 31, 2026

May 14, 2026

Announcement of a Lawsuit Filed against Nippon Shinyaku

May 8, 2026

Nippon Shinyaku Enters Collaboration with xFOREST Therapeutics on Drug Discovery Research Targeting RNA Structures

April 10, 2026

Nippon Shinyaku start co-promotion activities of OPSUMIT® Pediatric Dispersible Tablets 1mg and 2.5mg for the Treatment of Pulmonary Arterial Hypertension

March 17, 2026

Transfer of Marketing Authorization for Epileptic Seizures treatment FINTEPLA® Oral Solution 2.2 mg/mL

February 23, 2026

Notice Regarding Executive Personnel Changes

February 9, 2026

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2025

February 8, 2026

Nippon Shinyaku: ELZONRIS® I.V. Injection Receives Marketing Approval for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Japan

December 22, 2025

Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress

October 14, 2025

Orphan Drug Designation granted to Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis in Japan

September 30, 2025

FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy

September 19, 2025

FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis

September 9, 2025

NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases

July 1, 2025

Decks

The 5 newest of 8 decks. Every deck is listed under its year.